Should You Buy SpaceX After Its IPO? Here Are 3 Lessons to Heed from Warren Buffett

SpaceX’s IPO debuted at a $2.1 trillion market cap, implying a price-to-sales ratio above 112 on 2025 revenue of $18.7 billion. The article argues the stock is significantly overvalued versus Morningstar’s $63 per share DCF estimate, with only a 7% probability assigned to its $154 per share AI moonshot scenario. It also highlights governance risk, noting Elon Musk controls roughly 82.4% of voting power, making the setup unattractive for outside investors.

Analysis

The real takeaway is not just that the stock is expensive; it is that public-market price discovery is being distorted by scarcity, prestige, and index mechanics around a venue-sized private asset. That matters because once a mega-cap enters the tape at an extreme multiple, it can siphon attention and liquidity from adjacent “AI infrastructure” and growth-beta names even if they are the economically cleaner exposures. In the near term, the biggest beneficiaries are not the issuer’s peers but the market intermediaries: trading venues, market makers, and derivative desks that monetize elevated turnover and hedging demand.

The governance angle is more important than the valuation debate. Control concentration plus a broad, evolving transaction perimeter means minority holders are underwriting not only execution risk but also future capital allocation decisions they may not be able to influence. That creates a structural discount for any future equity raises or related-party combinations: each incremental financing event could be done at a lower effective quality of governance than the headline brand suggests, which raises the probability of post-IPO multiple compression even if operating results stay strong.

The contrarian miss is that the market may be treating optionality as if it were base case. A highly probabilistic “moonshot” embedded in a giant valuation can support sentiment, but it is not a robust earnings bridge; if the adjacent business line slips or capital intensity rises, the stock can de-rate quickly over 1-3 quarters because there is little margin for disappointment. The better trade is not to fight the company’s long-duration upside in absolute terms, but to express skepticism through relative value and event timing.

For MORN, the risk is less about one report and more about perceived credibility if the market repeatedly treats its fair-value work as wrong while the stock holds up. That could hurt narrative authority even if the business economics are unaffected. For NDAQ, the setup is tactically positive on volume and volatility, but the effect is front-loaded; if the IPO becomes a one-day capital-event rather than a sustained retail frenzy, the uplift fades quickly.

Key Decisions for Investors

• Short-dated call-spread hedge on the newly listed name: buy 1-3 month put spreads or bear call spreads to express de-rating risk, targeting a 20-30% downside move if initial enthusiasm cools and the lock-up/financing story starts to matter.
• Relative-value pair: long NDAQ / short MORN for 1-2 quarters. Use the IPO-driven volatility and trading-volume impulse as a near-term tailwind for exchange economics while fading the market’s reliance on single-point DCF anchors; aim for 2:1 payoff if listing activity remains elevated.
• Avoid initiating fresh long exposure in TSLA as a sympathy trade for AI/space optionality; if anything, use TSLA as a hedge against the possibility that conglomerate-style capital allocation and control concentration get rewarded by the market, which would pressure cleaner-growth peers.
• Buy the dip in NVDA only on evidence that capital formation in adjacent private AI infrastructure is converting into actual capex demand, not narrative-only sentiment. The better entry is after 2-4 weeks of post-IPO digestion, when attention shifts from headline valuation to procurement budgets.
• Monitor for secondary issuance or related-party transaction announcements over the next 3-6 months; those are the highest-risk catalyst windows for a sudden re-rating lower, and they are more actionable than the IPO date itself.